| Similar Articles |
|---|
 |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.   |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
The Motley Fool
December 29, 2006
Brian Lawler |
Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
September 28, 2007
Brian Orelli |
RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note. |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
Bio-IT World
Jul/Aug 2006 |
News Blast Health Solutions... Rna Interference... HIV Triple Combo... |
Chemistry World
October 2, 2006
Bea Perks |
RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
Bio-IT World
June 2005
Nancy Weil |
Dharmacon Signs Library Deal The biopharma is providing its genome-wide short-interfering RNA (siRNA) library to Millennium Pharmaceuticals. This is the first commercial siRNA collection that targets genes across the entire human genome, encompassing some 22,000 genes. |
The Motley Fool
August 1, 2007
Brian Orelli |
RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse? |
The Motley Fool
September 24, 2010
Brian Orelli |
So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership. |
Bio-IT World
October 2006 |
Briefs Kovac Joins Burrill... RNAi Nobel Prize... Hooray for Hood... ArQule Next... Initiative Accelerated... |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
Chemistry World
June 19, 2015
Rebecca Trager |
Alnylam accuses Dicerna of stealing trade secrets The US biopharmaceutical company Alnylam has filed a 'trade secret misappropriation' lawsuit against fellow Cambridge-based firm Dicerna. |
The Motley Fool
June 9, 2009
Brian Orelli |
Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out. |
Chemistry World
March 21, 2010
Simon Hadlington |
Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell. |
The Motley Fool
February 29, 2008
Brian Orelli |
RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease? |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
Bio-IT World
March 2006
Salamone & Davies |
Merck President Touts Technology Benefits Peter Kim, president of Merck Research Laboratories, says that small changes in the drug discovery and development process can yield significant benefits in bringing new drugs to market. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
The Motley Fool
January 9, 2009
Brian Orelli |
Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs? |
Bio-IT World
August 2005 |
News Blast Completes initial closing of financing to support RNAi-based therapies to treat macular degeneration... Mayo Clinic, Translational Genomics Research opens biomedical scientific facility... HistoRx appoints VP of research... Gates Foundation to share grant with 43 project winners... |
The Motley Fool
September 10, 2007
Brian Orelli |
Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note. |
Bio-IT World
March 2006 |
News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration... |
Chemistry World
October 4, 2006
Bea Perks |
Good Year for RNA Roger Kornberg, professor of structural biology at Stanford University, has been awarded the 2006 Nobel prize in chemistry for his work on the molecular basis of transcription. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Bio-IT World
November 2005
Robert M. Frederickson |
Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
February 28, 2011
Brian D. Pacampara |
Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease. |
The Motley Fool
October 23, 2007
Brian Orelli |
Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter. |
Fast Company
March 15, 2007
Tinker Ready |
Not Invented Here The next blockbuster drug could come from anywhere. It's up to Merck's scouts to find it. |
Chemistry World
November 5, 2007
Lewis Brindley |
Silencing the Pests Two teams of scientists have uncovered a new way to protect crops from two serious insect pests. The teams made use of a process called RNA interference to silence critical genes in the bodies of the insect larvae and stopped them growing. |
BusinessWeek
September 20, 2004
Amy Barrett |
Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession. |
The Motley Fool
November 18, 2010
Travis Hoium |
Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam. |
The Motley Fool
November 20, 2009
Brian Orelli |
This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit. |
The Motley Fool
February 18, 2011
John Keeling |
An Inside Look at Biotech Investing, Part 2 More on investing in "baby biotechs." |
Chemistry World
November 2006
Bea Perks |
Call That Chemistry? This year's Nobel prize in chemistry was a tour de force for crystallography, underscoring the vital role chemistry plays across the sciences. |
